Veru launches at-the-market offering of up to $21.8 million in common stock

Veru Inc. disclosed in a prospectus supplement dated July 2, 2026 that it had entered into a Sales Agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC relating to the sale of shares of its common stock.¹ Under the arrangement, Veru may offer and sell shares of common stock having an aggregate offering price of up to $21,800,000 from time to time through or to the applicable sales agent, acting as sales agent or principal.¹

The stock trades on the Nasdaq Capital Market under the symbol "VERU," and on July 1, 2026, the last reported sale price of the common stock was $3.16 per share.¹ The sales agents will receive compensation under the terms of the Sales Agreement at a commission rate of 3.0% of the gross proceeds of any shares of common stock sold.¹

Regarding use of proceeds, the company said it currently intends to use net proceeds from the sale of common stock, if any, for general corporate purposes, which may include additions to working capital, financing research and development, clinical trial and marketing expenditures, financing drug development activities, financing acquisitions, operating expenses and expenses relating to legal proceedings.¹ The filing also states that management will retain broad discretion regarding the allocation and use of any net proceeds.¹ The document does not tie this offering's proceeds specifically to development of enobosarm or sabizabulin, Veru's two lead drug candidates.

Separately, the filing noted that investors will experience immediate dilution, with an assumed sale of 6,898,734 shares at $3.16 per share producing dilution of $1.53 per share based on net tangible book value as of March 31, 2026.¹ The filing also flagged that the company's supply agreement with Novo Nordisk A/S could be terminated prior to completion of its PLATEAU Phase 2b clinical trial, including under a provision permitting termination for convenience on 60 days' notice.¹